Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid

Baldomero, H; Aljurf, M; Zaidi, SZA; Hashmi, SK; Ghavamzadeh, A; Elhaddad, A; Hamladji, RM; Ahmed, P; Torjemane, L; Abboud, M; Tbakhi, A; Khabori, MA; El Quessar, A; Bazuaye, N; Bekadja, MA; Adil, S; Fahmy, O; Ramzi, M; Ibrahim, A; Alseraihy, A; Ben Abdejalil, N; Sarhan, M; Huneini, MA; Mahmal, L; ElSolh, H; Hussain, F; Nassar, A; Al-Hashmi, H; Hamidieh, AA; Pasquini, M; Kodera, Y; Kröger, N; Mohty, M; Jaimovich, G; Rolon, JM; Paulson, K; Greinix, H; Weisdorf, D; Horowitz, M; Nunez, J; Gratwohl, A; Passweg, J; Koh, M; Szer, J; Niederwieser, D; Novitzky, N; East-Mediterranean (EMBMT) and African (AfBMT) Blood and Marrow Transplantation Groups and the Worldwide Network for Blood and Marrow Transplantation (WBMT).
Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends.
BONE MARROW TRANSPL. 2019; 54(3): 402-417. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Authors Med Uni Graz:
Greinix Hildegard

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Number of Figures: 3
| | |
Hematopoietic Stem Cell Transplantation (HSCT) activity was evaluated in the African (AFR)/EMRO region and compared to the global activity for the years 2006-2013. Data were obtained from 1570 teams in the 6 WHO continental regions. Of these, 29 (1.85%) of all teams were active in 12 of the 68 AFR/EMRO countries. They reported 2.331 (3.3%) of the worldwide 71.036 HSCT, and a transplant rate of 32.8 (TR; HSCT/10 million inhabitants; worldwide 128.5). This reflects still the lowest regional TR despite an increase of 90% since 2006. HSCT activity in AFR/EMRO countries was characterized by a higher use of allogeneic compared to autologous HSCT, an almost exclusive use of family donors, including haploidentical family donors. These findings contrast with the prevalence of autologous over allogeneic HSCT, and a higher frequency of unrelated HSCT in other parts of the world. Of note, the increase by 200% in HSCT for hemoglobinopathies from 2006 to 2013 (72 per year) in the AFR/EMRO region. This reflects the specific role of HSCT for these disease categories with high prevalence and incidence in the AFR/EMRO region. This report provides information for the competent authorities to foster adequate infrastructure. It urges transplant organization to optimize their cooperation.

© Med Uni GrazImprint